Excellent Response to Adapted Low-Dose 177Lu-PSMA-617 PSMA Therapy in Renal Compromise Patient

Sharjeel Usmani 1, Fareeda Al Kandari 1, Ibrahim Alrekhais 1, Shatha N Khalaf 1, Najeeb Ahmed 2

Affiliations

01 February 2022

-

doi: 10.1097/RLU.0000000000003912

Abstract

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy with 177Lu-PSMA-617 has shown promising results in patients with metastasized castration-resistant prostate cancer. We report a case of a 74-year-old man with metastatic prostate cancer with comorbidities of diabetes mellitus, hypertension, and chronic kidney disease. In order to minimize radiation burden to kidneys, a lower dose of 4 GBq of 177Lu-PSMA-617 was prescribed instead of the usual 6 to 7 GBq. There was significant decrease in prostate-specific antigen levels and symptoms. Renal profile remained stable. This case highlights that compromised renal function is not a definite contraindication to radionuclide therapy, and doses can be modified based on risk versus benefits.

Conflict of interest statement

Conflicts of interest and sources of funding: none declared.

Similar articles

Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy.

Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, Basu S, Das T, Banerjee S.Cancer Biother Radiopharm. 2021 Apr;36(3):292-304. doi: 10.1089/cbr.2020.3640. Epub 2020 May 5.PMID: 32379495

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.

Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U.J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16.PMID: 26985056 Clinical Trial.

Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.

Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, Stief C, Bartenstein P, Gratzke C, Lehner S, Rominger A.Oncotarget. 2017 Jan 10;8(2):3581-3590. doi: 10.18632/oncotarget.12240.PMID: 27683041 Free PMC article.

Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.

Kim YJ, Kim YI.Clin Nucl Med. 2018 Oct;43(10):728-734. doi: 10.1097/RLU.0000000000002210.PMID: 30059428 Review.

A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?

Gupta M, Karthikeyan G, Choudhury PS, Babu Koyyala VP, Sharma M, Jain P, Talwar V, Singh A, Rawal S.Cancer Invest. 2020 Sep;38(8-9):486-492. doi: 10.1080/07357907.2020.1811301. Epub 2020 Sep 14.PMID: 32804008 Review.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Ahmadzadehfar H, Eppard E, Kurpig S, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer. Oncotarget. 2016;7:12477–12488.
  2.  
    1. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091–1103. doi:10.1056/NEJMoa2107322. - DOI
  3.  
    1. Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81–85.
  4.  
    1. Yadav MP, Ballal S, Sahoo RK, et al. Radioligand therapy with 177Lu-PSMA for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2019;213:275–285.
  5.  
    1. Gallyamov M, Meyrick D, Barley J, et al. Renal outcomes of radioligand therapy: experience of 177lutetium–prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer. Clin Kidney J. 2019;13:1049–1055.
  6.  
    1. Baum RP, Kulkarni HR, Schuchardt C, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57:1006–1013.
  7.  
    1. Rathke H, Giesel FL, Flechsig P, et al. Repeated 177Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq. J Nucl Med. 2018;59:459–465.
  8.  
    1. Hofman MS, Violet J, Hicks RJ, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825–833.
  9.  
    1. Norouzi G, Aghdam RA, Hashemifard H, et al. Excellent response to lower dose of 177Lu-PSMA-617 in a metastatic castration-resistant prostate cancer patient with a transplanted kidney. Clin Nucl Med. 2019;44:483–484.
  10.  
    1. Zhang J, Kulkarni HR, Singh A, et al. 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney. J Nucl Med. 2019;60:1579–1586.

Page Navigation